227 related articles for article (PubMed ID: 36608132)
1. Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity.
Fu Z; Chen S; Zhu Y; Zhang D; Xie P; Jiao Q; Chi J; Xu S; Xue Y; Lu X; Song X; Cristofanilli M; Gradishar WJ; Kalinsky K; Yin Y; Zhang B; Wan Y
Sci Adv; 2023 Jan; 9(1):eadd6626. PubMed ID: 36608132
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
Zhu Y; Banerjee A; Xie P; Ivanov AA; Uddin A; Jiao Q; Chi JJ; Zeng L; Lee JY; Xue Y; Lu X; Cristofanilli M; Gradishar WJ; Henry CJ; Gillespie TW; Bhave MA; Kalinsky K; Fu H; Bahar I; Zhang B; Wan Y
J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38530357
[TBL] [Abstract][Full Text] [Related]
3. Association of connexin43 with E3 ubiquitin ligase TRIM21 reveals a mechanism for gap junction phosphodegron control.
Chen VC; Kristensen AR; Foster LJ; Naus CC
J Proteome Res; 2012 Dec; 11(12):6134-46. PubMed ID: 23106098
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
5. In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target.
Wang X; Tokheim C; Gu SS; Wang B; Tang Q; Li Y; Traugh N; Zeng Z; Zhang Y; Li Z; Zhang B; Fu J; Xiao T; Li W; Meyer CA; Chu J; Jiang P; Cejas P; Lim K; Long H; Brown M; Liu XS
Cell; 2021 Oct; 184(21):5357-5374.e22. PubMed ID: 34582788
[TBL] [Abstract][Full Text] [Related]
6. CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models.
Ye J; Gavras NW; Keeley DC; Hughson AL; Hannon G; Vrooman TG; Lesch ML; Johnston CJ; Lord EM; Belt BA; Linehan DC; Eyles J; Gerber SA
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37142292
[TBL] [Abstract][Full Text] [Related]
7. CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
[TBL] [Abstract][Full Text] [Related]
8. TRIM21-dependent target protein ubiquitination mediates cell-free Trim-Away.
Mevissen TET; Prasad AV; Walter JC
Cell Rep; 2023 Feb; 42(2):112125. PubMed ID: 36807144
[TBL] [Abstract][Full Text] [Related]
9. A Novel CD73 Inhibitor SHR170008 Suppresses Adenosine in Tumor and Enhances Anti-Tumor Activity with PD-1 Blockade in a Mouse Model of Breast Cancer.
Liu S; Li D; Liu J; Wang H; Horecny I; Shen R; Zhang R; Wu H; Hu Q; Zhao P; Zhang F; Yan Y; Feng J; Zhuang L; Li J; Zhang L; Tao W
Onco Targets Ther; 2021; 14():4561-4574. PubMed ID: 34466002
[TBL] [Abstract][Full Text] [Related]
10. Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma.
Shen A; Ye Y; Chen F; Xu Y; Zhang Z; Zhao Q; Zeng ZL
Front Immunol; 2022; 13():969034. PubMed ID: 36466881
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy and mechanism of CD73-TGFβ dual-blockade in a mouse model of triple-negative breast cancer.
Xing Y; Ren ZQ; Jin R; Liu L; Pei JP; Yu K
Acta Pharmacol Sin; 2022 Sep; 43(9):2410-2418. PubMed ID: 35082394
[TBL] [Abstract][Full Text] [Related]
12. SNAI1-dependent upregulation of CD73 increases extracellular adenosine release to mediate immune suppression in TNBC.
Hasmim M; Xiao M; Van Moer K; Kumar A; Oniga A; Mittelbronn M; Duhem C; Chammout A; Berchem G; Thiery JP; Volpert M; Hollier B; Noman MZ; Janji B
Front Immunol; 2022; 13():982821. PubMed ID: 36159844
[TBL] [Abstract][Full Text] [Related]
13. Redirecting the specificity of tripartite motif containing-21 scaffolds using a novel discovery and design approach.
VanDyke D; Xu L; Sargunas PR; Gilbreth RN; Baca M; Gao C; Hunt J; Spangler JB
J Biol Chem; 2023 Dec; 299(12):105381. PubMed ID: 37866632
[TBL] [Abstract][Full Text] [Related]
14. The ubiquitin-specific peptidase 22 is a deubiquitinase of CD73 in breast cancer cells.
Gregory S; Xu Y; Xie P; Fan J; Gao B; Mani N; Iyer R; Tang A; Wei J; Chaudhuri SM; Wang S; Liu H; Zhang B; Fang D
Am J Cancer Res; 2022; 12(12):5564-5575. PubMed ID: 36628293
[TBL] [Abstract][Full Text] [Related]
15. CD73: an emerging checkpoint for cancer immunotherapy.
Chen S; Wainwright DA; Wu JD; Wan Y; Matei DE; Zhang Y; Zhang B
Immunotherapy; 2019 Aug; 11(11):983-997. PubMed ID: 31223045
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
Buisseret L; Pommey S; Allard B; Garaud S; Bergeron M; Cousineau I; Ameye L; Bareche Y; Paesmans M; Crown JPA; Di Leo A; Loi S; Piccart-Gebhart M; Willard-Gallo K; Sotiriou C; Stagg J
Ann Oncol; 2018 Apr; 29(4):1056-1062. PubMed ID: 29145561
[TBL] [Abstract][Full Text] [Related]
17. The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer.
Liu J; Zhang C; Xu D; Zhang T; Chang CY; Wang J; Liu J; Zhang L; Haffty BG; Zong WX; Hu W; Feng Z
J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36749630
[TBL] [Abstract][Full Text] [Related]
18. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.
Jin D; Fan J; Wang L; Thompson LF; Liu A; Daniel BJ; Shin T; Curiel TJ; Zhang B
Cancer Res; 2010 Mar; 70(6):2245-55. PubMed ID: 20179192
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts.
Gao Z; Wang L; Song Z; Ren M; Yang Y; Li J; Shen K; Li Y; Ding Y; Yang Y; Zhou Y; Wei C; Gu J
Front Immunol; 2022; 13():954039. PubMed ID: 36131912
[TBL] [Abstract][Full Text] [Related]
20. E3 ubiquitin-protein ligase TRIM21-mediated lysine capture by UBE2E1 reveals substrate-targeting mode of a ubiquitin-conjugating E2.
Anandapadamanaban M; Kyriakidis NC; Csizmók V; Wallenhammar A; Espinosa AC; Ahlner A; Round AR; Trewhella J; Moche M; Wahren-Herlenius M; Sunnerhagen M
J Biol Chem; 2019 Jul; 294(30):11404-11419. PubMed ID: 31160341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
